Search Inside Peptides

A 15-amino-acid synthetic peptide studied in animal models of tendon, gut, and muscle healing. Lacks controlled human clinical trial evidence.

Synthetic peptide fragment modeled on Thymosin Beta-4; investigated in preclinical assays for actin sequestering, angiogenesis, and cell migration.

Naturally occurring copper-binding tripeptide investigated for extracellular matrix remodeling, collagen synthesis, and topical skin health.

A 16-amino-acid peptide encoded within mitochondrial DNA; studied in preclinical rodent models for metabolic homeostasis and AMPK activation.

Synthetic growth hormone releasing hormone (1-29) analogue engineered for extended half-life; evaluated in early Phase 1/2 human trials.

Selective pentapeptide ghrelin receptor agonist stimulating pulsatile pituitary growth hormone release without significant cortisol elevation.

FDA-approved stabilized GHRH analogue indicated for the reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

Modified 16-amino-acid fragment of human growth hormone studied in Phase 2b obesity trials, where it failed to demonstrate significant weight reduction.

The C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone; studied in preclinical colitis models for NF-kappaB inhibition.

Endogenous 37-amino-acid amphipathic peptide providing innate mucosal defense; evaluated in early human trials for venous leg ulcer healing.

Synthetic ACTH fragment analogue developed and clinically registered in Russia for stroke and cognitive recovery; unapproved by FDA or EMA.

Synthetic heptapeptide tuftsin derivative studied in Russian clinical cohorts for generalized anxiety disorder; unapproved in the US and Europe.

Synthetic tetrapeptide modeled on pineal extract epithalamin; investigated in rodent aging models for telomerase activation and pineal modulation.

FDA-approved cyclic melanocortin receptor agonist indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

Long-acting GLP-1 receptor agonist proven in large Phase 3 RCTs for type 2 diabetes glycemic control, obesity weight reduction, and cardiovascular risk reduction.

Dual GIP and GLP-1 receptor co-agonist approved by FDA for type 2 diabetes and chronic weight management following SURPASS and SURMOUNT clinical trials.

Once-daily GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with extensive long-term cardiovascular outcome trial data.

First-in-class synthetic exendin-4 GLP-1 receptor agonist approved by the FDA in 2005 for glycemic control in adult patients with type 2 diabetes.

FDA-approved synthetic analogue of human amylin used as mealtime adjunct therapy with insulin for glycemic regulation in type 1 and type 2 diabetes.

Synthetic cyclic somatostatin octapeptide analogue approved for acromegaly, severe diarrhea associated with metastatic carcinoid tumors, and VIPomas.